158985-08-1 Usage
General Description
3-[[4-(4-Iodophenyl)piperazin-1-yl]methyl]-1H-pyrrolo[2,3-b]pyridine is a chemical compound with the molecular formula C21H21IN4. It is a pyrrolopyridine derivative that contains a piperazine ring with an iodophenyl substituent. 3-[[4-(4-Iodophenyl)piperazin-1-yl]methyl]-1H-pyrrolo[2,3-b]pyridine has been studied for its potential pharmacological properties, including its role as a ligand for various receptors and its potential use in the development of new therapeutic agents. Its exact mechanism of action and specific biological activity have not been fully elucidated, but it has shown promise as a potential candidate for further drug development and research in the pharmaceutical and medical fields.
Check Digit Verification of cas no
The CAS Registry Mumber 158985-08-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,8,9,8 and 5 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 158985-08:
(8*1)+(7*5)+(6*8)+(5*9)+(4*8)+(3*5)+(2*0)+(1*8)=191
191 % 10 = 1
So 158985-08-1 is a valid CAS Registry Number.
158985-08-1Relevant articles and documents
Synthesis of 3-[[4-(4-[18F] fluorophenyl)piperazin-1-yl]methyl]-1H-pyrrolo[2,3-b]pyridine
Eskola, Olli,Bergman, Joergen,Lehikoinen, Pertti,Haaparanta, Merja,Groenroos, Tove,Forsback, Sarita,Solin, Olof
, p. 687 - 696 (2007/10/03)
3-[[4-(4-[18F]fluorophenyl)piperazin-1-yl]methyl] -1H-pyrrolo[2,3-b]pyridine, a candidate to image dopamine D4 receptors, was synthesised via electrophilic fluorination of a trimethylstannyl precursor with high specific radioactivity
Pyrrolo-pyridine derivatives
-
, (2008/06/13)
A class of pyrrolo[2,3-b]pyridine derivatives, substituted at the 3-position by a substituted piperazinylmethyl moiety, are antagonists of dopamine receptor subtypes within the brain, having a selective affinity for the dopamine D 4 receptor subtype over other dopamine receptor subtypes, and are accordingly of benefit in the treatment and/or prevention of psychotic disorders such as schizophrenia while manifesting fewer side-effects than those associated with classical neuroleptic drugs.